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provides a good therapeutic response with minimal adverse events, is a therapy option for periocular
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Abstract
Background: Due to the importance of function and cos-
metics, periocular skin malignancies represent a therapeutic 
challenge. Objective: To evaluate the safety and efficacy of 
radiotherapy (RT) treating periocular skin tumors. Methods: 
Data of patients with periocular tumors treated with grenz 
or soft X-rays at the University Hospital Zurich, Switzerland, 
between 2009 and 2014 were reviewed. Basal cell carcinoma 
(BCC) and squamous cell carcinoma (SCC) with associated in 
situ lesions, cutaneous melanoma, lentigo maligna (LM), cu-
taneous lymphoma and Kaposi’s sarcoma were included in 
the analysis. Results: We found 159 periocular lesions in 145 
patients. Overall recurrence was highest for actinic keratosis 
and Bowen’s disease (27%), melanoma (17%) and LM (15%), 
whereas SCC and BCC showed recurrence in 11 and 10%, re-
spectively. 45% of all recurrences occurred within 12 months 
after treatment, with a median time to recurrence of 13 
months (range 3–73). Conclusion: RT, which provides a good 
therapeutic response with minimal adverse events, is a ther-
apy option for periocular cutaneous malignancies.
© 2019 S. Karger AG, Basel
Introduction
Up to 10% of all skin malignancies occur in the peri-
ocular region [1]. Basal cell carcinoma (BCC) is the most 
common malignant eyelid tumor followed by squamous 
cell carcinoma (SCC), sebaceous cell carcinoma, Merkel 
cell carcinoma, cutaneous melanoma and other rare tu-
mors [1–3]. Likewise, in situ lesions, such as actinic kera-
tosis (AK) and Bowen’s disease (BD), can affect the peri-
ocular skin [2, 3]. Although the majority of cutaneous 
neoplasms can be treated by excision [4–9], excessive sur-
gical intervention in the periocular site may lead to ana-
tomical dysfunction and poor aesthetic outcome [10–12]. 
Less invasive approaches, such as photodynamic therapy 
or cryotherapy, represent a treatment option for superfi-
cial cutaneous neoplasms [7–9]. However, limited pene-
tration restricts their applicability in invasive tumors. Ra-
diotherapy (RT) with external beam radiation (using 
photons or electrons) and brachytherapy (radionuclide-
based or electronic) is an attractive treatment option for 
cutaneous tumors either as primary modality or adjunct 
to surgery [5–8, 13]. It has previously been reported that 
RT with grenz and soft X-rays is effective in cutaneous 
malignancies [14, 15], yet data on efficacy in the periocu-
lar area are still scarce. The aim of this retrospective study 
was to evaluate safety, cosmetic outcome, response to and 













































































For further details, see the online supplementary material (see 
www.karger.com/doi/10.1159/000496539 for all online suppl. ma-
terial) [16–18] (Fig. 1).
Results
In 145 patients, a total of 159 lesions were treated. The 
mean age at therapy start was 76 years (SD ±10.3) and the 
study cohort consisted of 86 females (54%) and 73 (46%) 
males. Nearly half of the treated lesions were BCCs (n = 
69, 43%), followed by lentigo maligna (LM) (n = 27, 
17%), SCC and cutaneous melanoma (each n = 18, 11%), 
AK/BD (n = 15, 9%) and cutaneous lymphoma/Kaposi’s 
sarcoma (n = 12, 8%) (see online suppl. Table 1). In 10% 
of the patients, 2 or 3 periocular lesions were simultane-
ously treated with RT. The distribution pattern of the le-
sions is shown in Figure 2. In 75% of the cases, RT was 
the 1st-line therapy, the rest was pretreated with surgery 
(16%) or conservative therapy (1% imiquimod in LM le-
sions or 4% PUVA therapy in mycosis fungoides pa-
tients). 38 patients (26%) were immunocompromised, 5 
of whom had more than 1 immunosuppressive disorder: 
12 patients had a diabetic disorder, 13 patients were on 
iatrogenic immunosuppression, while 10 suffered from 
lymphoma, 9 from solid cancer or hematopoietic in-
duced immunosuppression and 2 from alcohol depen-
dence.
The administered total dose per field ranged from 12 
to 120 Gy and was given at 2- to 5-day intervals for 3–13 
therapy sessions (fractions). Total dose and fractionation 
schedules were based on tumor subtype, size and location 
of the lesion. LM and melanoma lesions were treated with 
grenz or soft X-rays (10–20 kV), while other lesions were 
treated with soft rays (20–50 kV). Further details on RT 
parameters are summarized in online supplementary Ta-
ble 2. Most frequent irradiation-related toxicity (79%) 
was radiation dermatitis grade 1 (faint erythema) accord-
ing to Common Terminology Criteria for Adverse Events 
(CTCAE 4.03) [16], which did not require any interven-
tion and resolved within 4–6 weeks after the end of ther-
apy. In 27 cases moderate adverse events (grade 2 toxici-
ties, local intervention indicated) including radiation 
dermatitis (moderate erythema/edema and patchy moist 
desquamation, n = 21), infection of the wound (n = 2), 
symptomatic conjunctivitis (n = 2) or blepharitis (n = 1) 
and canalicular stenosis (n = 1) were documented. No 
grade 3 toxicities (severe adverse events) occurred under 
the RT. A patient example of the clinical outcome after 
irradiation is presented in Figure 3. Patients were reas-
sessed at the Dermatology Department 4 weeks after the 
end of RT, whereas further oncological follow-up was ei-
ther continued there (n = 60, 41%) or overtaken by the 
referring physician (n = 85, 59%). The mean follow-up 
time was 43 months (SD ±27).
Overall recurrence was 13% (20 out of 159 lesions), 
with the highest rate for AK/BD (n = 4, 27%), cutaneous 
melanoma (n = 3, 17%) and LM (n = 4, 15%), followed by 
SCC and BCC with a recurrence in 11% (n = 2) and 10% 
(n = 7), respectively. However, 2 SCCs (well- and moder-
ately differentiated subtype) and 1 BCC (nodular sub-
type) did not respond to RT and were therefore excluded 
from the progression-free survival analysis. 45% of all re-
currences occurred within 12 months after treatment, 
with a median time to recurrence of 13 months (range 
3–73 months). Relapse-free survival depending on diag-
nosis is presented in Figure 4.
File search in the clinical information system to identify 
patients who underwent periocular interventions at the 
University Hospital of Zurich between 2009 and 2014
730 patients assessed 
for eligibility
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Fig. 2. Distribution of periocular tumors by 
zone in the treatment population (cumula-
tive view).
Fig. 3. Clinical presentation and response to RT. LM lesion on the left lower eyelid in a 79-year-old woman. 
a Before treatment. b Local reaction after therapy with soft X-rays (20 kV, 6 Gy × 9 sessions, total 54 Gy). 


































Fig. 4. Relapse-free survival depending on 
diagnosis (Kaplan-Meier analysis). AK, ac-
tinic keratosis; BCC, basal cell carcinoma; 
LM, lentigo maligna; SCC, squamous cell 
carcinoma; other, cutaneous lymphoma 
(mycosis fungoides, primary cutaneous T-
cell lymphoma, diffuse large B-cell lym-















































































































Due to the importance of maintaining functionality 
and aesthetics, there is a need for subtle yet effective strat-
egies for treating periocular skin tumors. We retrospec-
tively evaluated the efficacy of RT with grenz and soft X-
rays in a large cohort of 145 patients with periocular skin 
neoplasms. As 2/3 of patients showed multiple malignant 
lesions and 18 patients developed a recurrence of 20 treat-
ed lesions, regular clinical examination in patients with a 
history of cutaneous malignancies is essential even after a 
successful treatment.
The periocular region can be affected by various be-
nign and (pre-)malignant tumors. Besides BCC, the most 
frequent malignant tumor, SCC, Merkel cell carcinoma, 
cutaneous melanoma, as well as in situ lesions and rare 
tumors can occur in this area, accounting for a total of 
5–10% of all cutaneous malignancies [1–3]. Not only may 
periocular tumors behave more aggressively and show 
higher recurrence rates, but they also represent a chal-
lenge for treatment compared to cutaneous lesions at oth-
er sites [10, 12, 19]. Previous data show that periocular 
neoplasms most frequently occur on the lower eyelid and 
the medial canthus [1, 2, 20–22], which are surgically 
challenging areas, carrying a risk of functional and aes-
thetic complications [10, 12, 19]. Moreover, as observed 
in our cohort too, periocular tumors tend to develop in 
fair-skin patients over 60 years of age, who have a history 
of significant sun exposure [20, 22] – all factors which are 
known to be associated with the development of skin can-
cer at any site [23–25], hence concomitant skin cancer is 
not rare. Among the therapy options for periocular ma-
lignancies, such as surgery, RT, cryotherapy, topical im-
munomodulatory drugs and photodynamic therapy, 
Mohs’ micrographic surgery or intraoperative frozen sec-
tion is the mainstay of treatment for invasive tumors [4–
9, 21]. The 5-year recurrence of periocular skin tumors 
after Mohs’ micrographic surgery is reported to be 2.0% 
in BCC [21] and 3.6% in SCC [20].
Irradiation is an attractive alternative where surgical 
excision may lead to anatomical dysfunction and poor 
aesthetic outcome, multiple lesions have to be treated si-
multaneously or as follow-up treatment after incomplete 
surgical excision [7, 8, 26–28]. Treatment with RT induc-
es nonrepairable DNA damage [29], and it has recently 
been reported to stimulate the activation of immune sys-
tem pathways [30, 31]. There are different modalities to 
treat a tumor by RT, and the suitable RT technique should 
be chosen for each patient individually. Depending on the 
clinical presentation, low-energy X-rays that penetrate 
only superficially, brachytherapy (for curved surfaces) or 
high-energy RT (photons or electrons) are used. The lat-
ter penetrates deeper tissues with relative skin sparing. 
However, when treating cutaneous lesions, deep beam 
penetration and skin sparing are usually not desirable. 
The delivery of low-energy kilovoltage photons by a su-
perficial/orthovoltage machine is preferable. In Switzer-
land specifically for the radiation of the skin, trained der-
matologists are allowed to perform superficial X-ray ther-
apy independently of radiation oncologists. Accordingly, 
we used grenz and soft X-rays in our cohort. These very-
low- to low-energy X-rays are directed from outside the 
body into the tumor and affect the epidermis and dermis 
while largely sparing deeper tissue [32]. In brachytherapy, 
however, a sealed radiation source is placed at the tumor 
site (either inside or next to the tumor tissue) [33]. Previ-
ous reviews systematically evaluated the outcome of 
brachytherapy and superficial RT in periocular skin tu-
mors [27, 34]. A review article on brachytherapy in non-
melanoma skin cancer of the eyelid concluded that 
brachytherapy provides high clinical efficacy (median lo-
cal control rate 95.2%) and good functional-cosmetic 
outcome (median 100%) [34]. In addition, especially in 
old and frail patients, brachytherapy is a safe treatment 
modality [35].
Farshad et al. [15] analyzed patients with LM and LM 
melanoma treated with grenz or soft X-rays. The overall 
recurrence was 7% and the mean time to recurrence 45.6 
months. Interestingly, all of the recurrent lesions were lo-
cated on the face. Another study on LM and early LM 
melanoma by Hedblad and Mallbris [36] evaluated the 
efficacy of grenz rays and reported a residual lesion in 15 
and recurrence in 58 out of 593 lesions, 73% of which re-
lapsed within 24 months after the end of treatment. This 
is consistent with our data (70% of recurrences within 24 
months, however in our cohort a smaller percentage in 
the group of melanocytic lesions) and emphasizes the im-
portance of follow-up for at least 2 years after the end of 
treatment.
The reported overall recurrence at 5 years after the RT 
is 13.8% in SCC [14] and 15.8% in BCC [37]. As far as the 
periocular localization is concerned, Fitzpatrick et al. [38] 
reported a 5-year tumor control rate of 95% for BCC and 
93.3% for SCC. In our cohort we found a recurrence rate 
of 6% after 1 year and 9% after 2 years in 112 patients, who 
were followed up for at least 24 months. Overall recur-
rence in BCC was 10% (n = 7), in SCC 11% (n = 2), in LM 
15% (n = 4), in cutaneous melanoma 17% (n = 3) and in 
AK/BD 27% (n = 4), with a median time to recurrence of 










































































neoplasms were the first to recur, all of the recurred SCC 
and AK have done so within 16 months after the end of 
RT. However, time to recurrence must be evaluated cau-
tiously as it is highly dependent on the follow-up time 
points. In periocular AK, previous studies on efficacy of 
topical 5% fluorouracil reported a recurrence rate of 23% 
with a median time to recurrence of 12 months (range 
6–19 months) [39], while another study used 3% diclo-
fenac gel at periocular sites and showed recurrence of 50% 
[40], with both therapies demonstrating results by far 
worse than those seen in RT.
In our analyses we could not find any factor for a high-
er risk of recurrence. Location of the lesion (p = 0.1572), 
irradiation field size (p = 0.189), if the lesion was recur-
rent at therapy start (p = 0.08787) or subtypes in BCCs 
(p = 0.5026) and differentiation in SCCs (p = 0.8251) did 
affect the local recurrence rate, respectively. In LM pa-
tients with recurrence, 3 out of 4 patients had punctate 
hyperpigmentation in the treated field 4 weeks after the 
end of RT. As postinflammatory hyperpigmentation can-
not be differentiated from a persistent lesion, a regular 
follow-up with a timely histological analysis should be 
done in these patients. Immunosuppressed patients are 
not only known to have an up to 90 times increased risk 
of developing skin cancer [41, 42], but also to follow a 
more aggressive course [43]. In our study, however, the 
status of immunosuppression did not differ significantly 
between the patients who developed and who did not de-
velop a relapse (11.4 vs. 14.2%, respectively, p > 0.05).
Treatment tolerability in RT with grenz and soft X-
rays is good as the therapy-induced acute radiodermatitis 
occurs only within the treated site and heals within 4–6 
weeks after completion of treatment [27, 28, 36]. In our 
cohort, neither grade > 3 adverse events nor major disfig-
urement occurred. One patient with a medial canthus le-
sion developed a canalicular obstruction during treat-
ment, which is a known complication of intervention in 
this anatomical area [44, 45], and this was treated with a 
punctal dilation by the ophthalmologist. To preserve the 
integrity of the drainage system, Berman et al. [27] sug-
gested to place a nasolacrimal stent prior to the start of 
RT in the medial canthus. We also recommend planning 
a dermatological follow-up appointment 4 weeks after the 
last irradiation session for an evaluation of early side ef-
fects and referral to a specialist, if needed, as well as for an 
assessment of treatment efficacy.
In conclusion, RT with grenz and soft X-rays is a rea-
sonable therapy modality for periocular skin malignan-
cies, especially in patients of advanced age or if patients 
present with significant comorbidities. It provides high 
efficacy with limited side effects and good cosmetic out-
come. However, local recurrences can occur, and there-
fore a regular clinical follow-up for at least 24 months 
after successful irradiation therapy is crucial.
Key Message
Radiotherapy with grenz and soft X-rays is a valuable and safe 
treatment modality for periocular skin malignancies.
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